PharmaShots Weekly Snapshots (October 28 – October 30, 2024)
This week PharmaShots’ news was all about the updates on Clinical Trials, Pharma, Regulatory & M&A. Check out our full report below:
Biogen Reports Positive Data of Felzartamab to Treat IgA Nephropathy (IgAN) at ASN Kidney Week 2024
Read More: Biogen
Novartis Reports Data from P-III (APPEAR-C3G) Study of Fabhalta (Iptacopan) in C3 Glomerulopathy (C3G)
Read More: Novartis
Shuttle Pharma Reports the Completion of Clinical Trial Site Enrollment for the P-II Study of Ropidoxuridine for Glioblastoma
Read More: Shuttle Pharma
EyePoint Pharmaceuticals Reports Data From Ongoing P-II (VERONA) Study of Duravyu in Diabetic Macular Edema (DME)
Read More: EyePoint Pharmaceuticals
Rallybio Receives the CTAs’ Approval for P-II Study of RLYB212 to Treat HPA-1a Alloimmunization and FNAIT
Read More: Rallybio
Modalis Therapeutics’ MDL-101 Gains the US FDA’s Orphan Drug Designation to Treat Congenital Muscular Dystrophy Type 1A (LAMA2-CMD)
Read More: Modalis Therapeutics
European Patent Office (EPO) Grants Approval to Biogen’s Tecfidera Patent
Read More: Biogen
Iterum Therapeutics’ Orlynvah (Oral Sulopenem) Receives the US FDA’s Approval to Treat uUTIs
Read More: Iterum Therapeutics
Kind Pharmaceutical’s AND017 Gains the US FDA’s Orphan Drug Designation to Treat SCD
Read More: Kind Pharmaceutical
AstraZeneca’s Fasenra Receives EU Approval for Eosinophilic Granulomatosis with Polyangiitis
Read More: AstraZeneca
The US FDA Approves Novartis’ Scemblix for Newly Diagnosed Ph+ CML in Chronic Phase
Read More: Novartis
Shorla Oncology Reports the US FDA’s Expanded Approval of Jylamvo for Pediatric Indications
Read More: Shorla Oncology
Johnson & Johnson’s Edurant Receives the EC Approval for Expanded Use as HIV-1 Therapy in Pediatric Individuals
Read More: Johnson & Johnson
Astellas Reports MAA Withdrawn for Avacincaptad Pegol (ACP) in the EU
Read More: Astellas
Monte Rosa Therapeutics and Novartis Collaborate to Advance VAV1-directed Molecular Glue Degraders (MGD)
Read More: Monte Rosa Therapeutics & Novartis
Lisata Therapeutics and the University of Cincinnati Enters into Sponsored Agreement for Certepetide to Treat Endometriosis
Read More: Lisata Therapeutics and the University of Cincinnati
Biogen and Neomorph Collaborate to Discover and Develop Molecular Glue Degraders (MGD)
Read More: Biogen and Neomorph
GSK to Acquire Chimagen Biosciences’ CMG1A46, Expanding its Immunology Pipeline
Read More: GSK and Chimagen Biosciences
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com